Sino-US firm Eccogene Inc. has announced the closure of a Series B financing round, raising RMB180 million (USD 25 million). The round was co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, with participation from new investors Rockbleu Capital, YuFu Investment, Huajin Capital, and Elikon Venture, as well as existing investors Delos Capital, Oriza Seed Capital, and Qingsong Capital.
Eccogene’s Focus on Translational Medicine for Metabolic and Immune-Related Diseases
Eccogene is dedicated to the discovery and development of translational medicine for metabolic and immune-related diseases. The company’s clinical pipelines include ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRb full agonist for NASH and lipid disorders. Additionally, Eccogene is developing ECC0509, an SSAO/VAP-1 inhibitor that is nearing the end of its Phase I study.
Use of Proceeds to Accelerate Clinical and Preclinical Programs
The funds raised will be utilized to support the Phase I clinical studies for ECC5004 and ECC4703, accelerating their progress towards becoming viable treatment options for patients. Furthermore, the proceeds will also be directed towards advancing Eccogene’s preclinical programs, which focus on developing new therapies for metabolic and immunological diseases.-Fineline Info & Tech
